Fed. Circ. Upholds AstraZeneca's Crestor Patent
The Federal Circuit on Friday affirmed the validity of the patent covering AstraZeneca PLC's cholesterol-reducing drug Crestor, rejecting arguments by generics makers including Mylan Pharmaceuticals Inc. that it is invalid and...To view the full article, register now.
Already a subscriber? Click here to view full article